


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 209/14, A61K 31/40, 31/405, C07D 209/26	A1	(11) International Publication Number: WO 96/25397 (43) International Publication Date: 22 August 1996 (22.08.96)
(21) International Application Number: PCT/CA96/00080 (22) International Filing Date: 8 February 1996 (08.02.96) (30) Priority Data: 388,929 15 February 1995 (15.02.95) US (60) Parent Application or Grant (63) Related by Continuation US 388,929 (CON) Filed on 15 February 1995 (15.02.95) (71) Applicant (for all designated States except US): MERCK FROSST CANADA INC. [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): GALLANT, Michel [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA). GAREAU, Yves [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA). GUAY, Daniel [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA). LABELLE, Marc [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec		H9H 3L1 (CA). PRASIT, Petpiboon [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA). (74) Agent: MURPHY, Kevin, P.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College, Montreal, Quebec H3A 2Y3 (CA). (81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.
(54) Title: INDOLE DERIVATIVES WITH AFFINITY FOR THE CANNABINOID RECEPTOR (57) Abstract <p>Disclosed are indole derivatives of formula (I) having activity on the cannabinoid receptors and the methods of their preparation. The compounds are useful for lowering ocular intraocular pressure and treating glaucoma because of the activity of the cannabinoid receptor.</p> <div style="text-align: right;">  <div style="position: absolute; right: 0; top: 0;">(I)</div> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

TITLE OF THE INVENTIONINDOLE DERIVATIVES WITH AFFINITY FOR THE
CANNABINOID RECEPTOR5 BACKGROUND OF THE INVENTION


The terms cannabinoid or cannabimimetic compound apply to compounds which produce a physiological effect similar to that of the plant *Cannabis Sativa*, or a compound that has affinity for the cannabinoid receptors CB₁ or CB₂. See Matsuda, L.; Lolait, S.J.; Brownstein, M.J.; Young, A.C.; Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature*, **1990**, 346, 561-564; Munro, S.; Thomas, K.L.; Abu-Shaar, M. Molecular characterization of the peripheral receptor of cannabinoids. *Nature*, **1993**, 1993, 61-65. Examples of such compounds are Δ^9 -THC and its analogs (Razdan, R.K. Structure activity relationship in the cannabinoids. *Pharmacol. Rev.*, **1986**, 38, 75-149), WIN-55212-2 and its analogs (D'Ambra, T.E.; Estep, K.G.; Bell, M.R.; Eissenstat, M.A.; Josef, K.A.; Ward, S.J.; Haycock, D.A.; Baizman, E.R.; Casiano, F.M.; Beglin, N.C.; Chippari, S.M.; Grego, J.D.; Kullnig, R.K.; Daley, G.T. Conformationally restrained analogues of Pravadoline: Nanomolar potent, enantioselective, aminoalkylindole agonist of the cannabinoid receptor. *J. Med. Chem.*, **1992**, 35, 124-135; Bell, M.R.; D'Ambra, T.E.; Kumar, V.; Eissenstat, M.A.; Hermann, J.L.; Wetzel, J.R.; Rosi, D.; Philion, R.E.; Daum, S.J.; Hlasta, D.J.; Kullnig, R.K.; Ackerman, J.H.; Haubrich, D.R.; Luttinger, D.A.; Baizman, E.R.; Miller, M.S.; Ward, S.J. Antinociceptive aminoalkylindoles. *J. Med. Chem.*, **1991**, 34, 1099-1100), CP-55940 and its analogs (Johnson, M.R.; Melvin, L.S. The discovery of non-classical cannabinoid analgetics. In "Cannabinoids as therapeutic agents", **1986**, Mechoulam, R., Ed., CRC Press: Boca Raton FL, pp.121-145), SR141716A and its analogs (Barth, F.; Casellas, P.; Congy, C.; Martinez, S.; Rinaldi, M. Nouveaux derives du pyrazole. procede pour leur preparation et composition pharmaceutiques les contenant. French Patent 2692575-A1, **1992**; Barth, F.; Heaulme, M.; Shire, D.; Calandra, B.; Congy, C.; Martinez, S.; Maruani, J.; Neliat,

- 2 -

G.; Caput. D.; Ferrara, P.; Soubrie, P.; Breliere, J-C.; Le Fur, G.; Rinaldi-Carmona, M. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. International Cannabis Research Society Conference Abstract, **July 1994**, L'EstÈrel, Canada, p. 33), and
 5 anandamide (Devane, W.A.; Hanus, L.; Breuer, A.; Pertwee, R.G.; Stevenson, L.A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science*, **1992**, 258, 1946-1949) and its
 10 analogs. Anandamide has been termed the endogenous ligand of the CB₁ receptor, as it is synthesized near its site of action and is potent and selective for the CB₁ receptor.

The biological activity of cannabinoids has been extensively reviewed. See Hollister, L.E. Health aspects of Cannabis. *Pharmacol. Rev.*, **1986**, 38, 1-20. Their usefulness in various disease states has been
 15 discussed. See The therapeutic potential of marihuana. Cohen, S. and Stillman, R.C., eds. Plenum: New York, **1976**.

Additionally, US patents 4,973,587 and 5,013,837 (Ward et al.) disclose compounds of formula 1:



1


having antiglaucoma compositions where:

- R₂ is hydrogen, lower alkyl, chloro or fluoro;
 30 R₃ is phenyl (or phenyl substituted by from one to three substituents selected from halogen, lower alkoxy, lower alkoxyethyl, hydroxy, lower alkyl, amino, lower alkylamino, di-lower alkylamino or lower alkylmercapto), methylenedioxyphenyl, benzyl, styryl, lower alkoxyethyl,

- 3 -

- 1- or 2-naphthyl,) or 1- or 2-naphthyl substituted by from one to two substituents selected from lower alkyl, lower alkoxy, halo or cyano), (1H-imidazol-1-yl)naphthyl, 2-(1-naphthyl)ethenyl, 1-(1,2,3,4-tetrahydronaphthyl), anthryl, phenanthryl, pyrenyl, 2-, 3-, 4-, 5-, 6- or 7-benzo[b]furyl, 2 or 3-benzo[b]thienyl, 5-(1H-benzimidazolyl) or 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl;
- R₄ is hydrogen or lower alkyl, hydroxy, lower alkoxy or halo in the 4-, 5-, 6- or 7-positions;
- X is O or S;
- Alk is lower alkylene having the formula (CH₂)_n where n is the integer 2 or 3, or such lower-alkylene substituted by a lower-alkyl group; and
- N=B is N,N-di-lower alkylamino, 4-morpholinyl, 2-lower alkyl-4-morpholinyl, 3-lower alkylmorpholinyl, 1-pyrrolidinyl, 1-piperidinyl or 3-hydroxy-1-piperidinyl.

US patent 5,081,122 (Ward) discloses compounds of formula 2:




- having antiglaucoma compositions where:
- Ar is lower alkoxyphenyl or 1- or 2-naphthyl;
- R₃ is hydrogen or lower alkyl;
- Alk is lower alkylene containing from two to four carbon atoms.

- 4 -

The present compounds differ from Ward's (formula 1 and 2) primarily in having a carbonyl on the nitrogen of the indole while it is at the 4-position in the case of the US patent 5,081,122.

EP 0 444 451 generically discloses a compound of formula

5 3:



15 useful as analgesic, anti-rheumatic, anti-inflammatory or anti-glaucoma agents where:

R₂ is hydrogen, lower alkyl;

20 R₃ is phenyl (or phenyl substituted by from one to three substituents selected from halogen, lower alkoxy, hydroxy, lower alkyl, nitro, amino, lower alkylamino, di-lower alkylamino, loweralkylmercapto, lower alkylsulfinyl, lower alkylsulfonyl and methylenedioxy), 2- or 4-biphenyl or 1- or 2-naphthyl (or 1- or 2-naphthyl substituted by from one to two substituents selected from lower alkyl, lower alkoxy, halogen, lower alkylmercapto, lower alkylsulfinyl, lower alkylsulfonyl and trifluoromethyl);

25 R₄ is hydrogen or from one to two substituents selected from loweralkyl, hydroxy, lower alkoxy, and halogen at the 4-, 5-, 6- or 7- positions;

30 Alk is lower alkylene containing from two to four carbon atoms which may contain a lower alkyl group;


n is 0 or 1;

Het is an aliphatic heterocycle, 2-piperazinyl and 2-indolinyl.

- 5 -

The present compound differs from formula 3 primarily in having a carbonyl on the nitrogen of the indole.


U.S. Patent 3,489,770 generically discloses compound having the following formula 4:



4

The compounds are said to have anti-inflammatory, hypotensive, hypoglycemic and CNS activities. Although not within the ambit of the above-defined genus, the patent also discloses a variety of species where R^2 is an arylcarbonyl group.

British Patent 1,374,414 and U.S. Patent 4,021,431 generically discloses compounds having the following structural formula 5:



5

The compounds are useful as anti-inflammatory agents. Although not within the ambit of the above-defined genus, the patent also discloses a variety of species where A is an arylcarbonyl group.

- 6 -


SUMMARY OF THE INVENTION

The present invention relates to indoles having activity on the cannabinoid receptor CB2 and the methods of their preparation.

Because of this activity on the cannabinoid receptor, the compounds of the present invention are useful for lowering the IOP (intra ocular pressure).

DETAIL DESCRIPTION OF THE INVENTION

The compounds of the invention can be summarized by formula I:



wherein:

- 20 R^1 is H, lower alkyl, aryl, benzyl, or lower fluorinated alkyl;
 R^{2-4} is independently, H, lower alkyl, lower fluorinated alkyl, halogen, NO_2 , CN, $-(\text{CR}^7_2)_m\text{-OR}^1$, $-(\text{CR}^7_2)_m\text{-S(O)}_n\text{R}^6$, or $-(\text{CR}^7_2)_m\text{-R}^6$;
 25 R^5 is H, lower alkyl, aryl, or benzyl;
 R^6 is lower alkyl, aryl, benzyl, or $\text{N(R}^5)_2$;
 R^7 is H, or lower alkyl;
 R^8 is R^7 , lower fluorinated alkyl, halogen, OR^7 , or lower alkyl thio;
 30 R^9 is R^7 , lower fluorinated alkyl, halogen, OR^7 , or lower alkyl thio;
 Q_1 is H, OR^7 , CHO, CN, CO_2R^7 , C(O)SR^7 , $\text{S(O)}_n\text{R}^6$, HET or $\text{N(R}^7)_2$, wherein two R^7 groups may be joined to form a

- 7 -

pyrrolidine, piperidine, piperazine, morpholine or
thiomorpholine ring and their quaternary methyl
ammonium salts;
 5 Q_2 is phenyl, naphthyl, quinoliny, furanyl, thienyl, pyridinyl,
 anthracyl, benzothienyl, benzofuranyl or thieno[3,2-b]-
 pyridinyl, mono-, di- or trisubstituted with R^8 ;
 HET is is a diradical of benzene, thiazole, thiophene, or furan,
 substituted with one or two R^9 groups;
 Z is CO or a bond.
 10 m is 0-6; and
 n is 0,1, or 2.

Definitions

15 The following abbreviations have the indicated meanings:

	DCC	=	1,3-dicyclohexylcarbodiimide
	DIBAL	=	diisobutyl aluminum hydride
	DMAP	=	4-(dimethylamino)pyridine
20	DMF	=	N,N-dimethylformamide
	DMSO	=	dimethyl sulfoxide
	HMPA	=	hexamethylphosphoramide
	KHMDS	=	potassium hexamethyldisilazane
	LDA	=	lithium diisopropylamide
25	MCPBA	=	metachloroperbenzoic acid
	Ms	=	methanesulfonyl = mesyl
	MsO	=	methanesulfonate = mesylate
	NBS	=	N-bromosuccinimide
	PCC	=	pyridinium chlorochromate
30	PDC	=	pyridinium dichromate
	Ph	=	phenyl
	PPTS	=	pyridinium p-toluene sulfonate
	pTSA	=	p-toluene sulfonic acid
	Pye	=	pyridinediyl

- 8 -

	r.t.	=	room temperature
	rac.	=	racemic
	Tf	=	trifluoromethanesulfonyl = triflyl
	TfO	=	trifluoromethanesulfonate = triflate
5	THF	=	tetrahydrofuran
	THP	=	tetrahydropyran-2-yl
	TLC	=	thin layer chromatography
	Ts	=	p-toluenesulfonyl = tosyl
	TsO	=	p-toluenesulfonate = tosylate
10	Tz	=	1H (or 2H)-tetrazol-5-yl
	SO ₂	=	=O=S=O

Alkyl group abbreviations

	Me	=	methyl
15	Et	=	ethyl
	n-Pr	=	normal propyl
	i-Pr	=	isopropyl
	n-Bu	=	normal butyl
	i-Bu	=	isobutyl
20	s-Bu	=	secondary butyl
	t-Bu	=	tertiary butyl

The term alkyl means linear, branched, and cyclic structures and combinations thereof.

25 "Lower alkyl" means alkyl groups of from 1 to 7 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, s- and t-butyl, pentyl, hexyl, heptyl, cyclopropyl, cyclohexylmethyl, and the like.

"Lower alkoxy" means alkoxy groups of from 1 to 7
30 carbon atoms of a straight, branched, or cyclic configuration. Examples of lower alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy, and the like.

"Lower alkylthio" means alkylthio groups of from 1 to 7 carbon atoms of a straight, branched, or cyclic configuration.

- 9 -

Examples of lower alkylthio groups include methylthio, propylthio, isopropylthio, cycloheptylthio, etc. By way of illustration, the propylthio group signifies -SCH₂CH₂CH₃.

"Aryl" includes phenyl and phenyl monosubstituted by halogen, a lower alkoxy or a lower alkylthio group.

"Lower fluorinated alkyl" means alkyl groups of from 1 to 7 carbon atoms in which one or more of the hydrogen atoms has been replaced by fluorine.

"Benzyl" includes mono or disubstitution on the aromatic ring by halogen, lower alkoxy or lower alkylthio groups. The hydrogens of the methylene moiety could be replaced by lower alkyl.

Halogen includes F, Cl, Br, and I.

It is intended that the definition of any substituent (e.g., R⁵) in a particular molecule be independent of its definition elsewhere in the molecule. Thus, -N(R⁵)₂ represents -NH₂, -NHCH₃, -NHC₆H₅, etc.

Optical Isomers - Diastereomers

Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention is meant to comprehend such possible diastereomers as well as their racemic and resolved, enantiomerically pure forms and pharmaceutically acceptable salts thereof.

Salts

The pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt, thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from

- 10 -

pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-
5 dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines,
10 theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.

When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic,
15 benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like. Particularly preferred are citric, hydrobromic,
20 hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.

It will be understood that in the discussion of methods of treatment which follows, references to the compounds of Formula I are meant to also include the pharmaceutically acceptable salts.

Examples of the novel compounds of this invention are
25 as follows:

- 11 -

TABLE 1 *m = 1 EXCEPT NOTED OTHERWISE

CPD	R ¹	R ²	R ³	R ⁴	R ⁷ *	Z	Q ₁	Q ₂
1	CH ₃	H	H	Cl	H	-	4-MORPHOLINE	2-CHLOROPHENYL
2	CH ₃	H	H	F	H	-	4-MORPHOLINE	2-CHLOROPHENYL
3	CH ₃	H	H	Br	H	-	4-MORPHOLINE	2-CHLOROPHENYL
4	CH ₃	H	H	OCH ₃	H	-	4-MORPHOLINE	2-CHLOROPHENYL
5	CH ₃	H	H	CF ₃	H	-	4-MORPHOLINE	2-CHLOROPHENYL
6	CH ₃	H	H	C ₂ F ₅	H	-	4-MORPHOLINE	2-CHLOROPHENYL
7	CH ₃	H	H	NO ₂	H	-	4-MORPHOLINE	2-CHLOROPHENYL
8	CH ₃	H	H	Ph	H	-	4-MORPHOLINE	2-CHLOROPHENYL
9	CH ₃	H	H	NH ₂	H	-	4-MORPHOLINE	2-CHLOROPHENYL
10	CH ₃	H	H	N(CH ₃) ₂	H	-	4-MORPHOLINE	2-CHLOROPHENYL
11	CH ₃	H	H	N(Bn) ₂	H	-	4-MORPHOLINE	2-CHLOROPHENYL
12	CH ₃	H	H	N(Ph) ₂	H	-	4-MORPHOLINE	2-CHLOROPHENYL
13	CH ₃	H	H	CN	H	-	4-MORPHOLINE	2-CHLOROPHENYL
14	CH ₃	H	H	SO ₂ ClH ₃	H	-	4-MORPHOLINE	2-CHLOROPHENYL
15	CH ₃	H	H	SO ₂ Ph	H	-	4-MORPHOLINE	2-CHLOROPHENYL
16	CH ₃	H	H	SO ₂ NH ₂	H	-	4-MORPHOLINE	2-CHLOROPHENYL
17	CH ₃	H	H	SO ₂ NHCH ₃	H	-	4-MORPHOLINE	2-CHLOROPHENYL
18	CH ₃	H	H	SO ₂ N(CH ₃) ₂	H	-	4-MORPHOLINE	2-CHLOROPHENYL
19	CH ₃	H	H	CH ₃	H	-	4-MORPHOLINE	2-CHLOROPHENYL
20	CH ₃	H	H	C ₂ H ₅	H	-	4-MORPHOLINE	2-CHLOROPHENYL

- 12 -

TABLE 1 (CONTINUED)

CPD	R ¹	R ²	R ³	R ⁴	R ^{7*}	Z	Q ¹	Q ²
21	CH ₃	H	H	n-C ₃ H ₇	H	-	4-MORPHOLINE	2-CHLOROPHENYL
22	CH ₃	H	H	OH	H	-	4-MORPHOLINE	2-CHLOROPHENYL
23	CH ₃	H	H	OC ₂ H ₅	H	-	4-MORPHOLINE	2-CHLOROPHENYL
24	CH ₃	H	H	OC ₃ H ₇	H	-	4-MORPHOLINE	2-CHLOROPHENYL
25	CH ₃	H	H	OPh	H	-	4-MORPHOLINE	2-CHLOROPHENYL
26	CH ₃	H	H	OBn	H	-	4-MORPHOLINE	2-CHLOROPHENYL
27	CH ₃	H	H	OCF ₃	H	-	4-MORPHOLINE	2-CHLOROPHENYL
28	CH ₃	H	H	Cl	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
29	CH ₃	H	H	F	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
30	CH ₃	H	H	Br	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
31	CH ₃	H	H	OCH ₃	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
32	CH ₃	H	H	CF ₃	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
33	CH ₃	H	H	C ₂ F ₅	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
34	CH ₃	H	H	NO ₂	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
35	CH ₃	H	H	Ph	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
36	CH ₃	H	H	NH ₂	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
37	CH ₃	H	H	N(CH ₃) ₂	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
38	CH ₃	H	H	N(Bn) ₂	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
39	CH ₃	H	H	N(Ph) ₂	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
40	CH ₃	H	H	CN	H	CO	4-MORPHOLINE	2-CHLOROPHENYL

TABLE I (CONTINUED)

CPD	R ¹	R ²	R ³	R ⁴	R ^{7*}	Z	Q ₁	Q ₂
41	CH ₃	H	H	SO ₂ CH ₃	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
42	CH ₃	H	H	SO ₂ Ph	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
43	CH ₃	H	H	SO ₂ NH ₂	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
44	CH ₃	H	H	SO ₂ NHCH ₃	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
45	CH ₃	H	H	SO ₂ NCH ₃) ₂	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
46	CH ₃	H	H	CH ₃	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
47	CH ₃	H	H	C ₂ H ₅	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
48	CH ₃	H	H	n-C ₃ H ₇	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
49	CH ₃	H	H	OH	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
50	CH ₃	H	H	OC ₂ H ₅	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
51	CH ₃	H	H	OC ₃ H ₇	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
52	CH ₃	H	H	OPh	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
53	CH ₃	H	H	OBn	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
54	CH ₃	H	H	OCF ₃	H	CO	4-MORPHOLINE	2-CHLOROPHENYL
55	CH ₃	H	H	H	H	-	4-MORPHOLINE	2,3-DICHLOROPHENYL
56	CH ₃	H	H	F	H	-	4-MORPHOLINE	2,3-DICHLOROPHENYL
57	CH ₃	H	H	Cl	H	-	4-MORPHOLINE	2,3-DICHLOROPHENYL
58	CH ₃	H	H	OCH ₃	H	-	4-MORPHOLINE	2,3-DICHLOROPHENYL

- 14 -

TABLE 1 (CONTINUED)

CPD	R ¹	R ²	R ³	R ⁴	R ^{7*}	Z	Q ₁	Q ₂
59	CH ₃	H	H	OCF ₃	H	-	4-MORPHOLINE	2,3-DICHLOROPHENYL
60	CH ₃	H	H	CF ₃	H	-	4-MORPHOLINE	2,3-DICHLOROPHENYL
61	CH ₃	H	H	SO ₂ CH ₃	H	-	4-MORPHOLINE	2,3-DICHLOROPHENYL
62	CH ₃	H	H	SO ₂ N(CH ₃) ₂	H	-	4-MORPHOLINE	2,3-DICHLOROPHENYL
63	CH ₃	H	H	H	H	-	4-MORPHOLINE	1-NAPHTHYL
64	CH ₃	H	H	F	H	-	4-MORPHOLINE	1-NAPHTHYL
65	CH ₃	H	H	Cl	H	-	4-MORPHOLINE	1-NAPHTHYL
66	CH ₃	H	H	OCH ₃	H	-	4-MORPHOLINE	1-NAPHTHYL
67	CH ₃	H	H	OCF ₃	H	-	4-MORPHOLINE	1-NAPHTHYL
68	CH ₃	H	H	CF ₃	H	-	4-MORPHOLINE	1-NAPHTHYL
69	CH ₃	H	H	SO ₂ CH ₃	H	-	4-MORPHOLINE	1-NAPHTHYL
70	CH ₃	H	H	SO ₂ N(CH ₃) ₂	H	-	4-MORPHOLINE	1-NAPHTHYL
71	CH ₃	H	H	H	H	-	4-MORPHOLINE	2-NAPHTHYL
72	CH ₃	H	H	F	H	-	4-MORPHOLINE	2-NAPHTHYL
73	CH ₃	H	H	Cl	H	-	4-MORPHOLINE	2-NAPHTHYL
74	CH ₃	H	H	OCH ₃	H	-	4-MORPHOLINE	2-NAPHTHYL
75	CH ₃	H	H	OCF ₃	H	-	4-MORPHOLINE	2-NAPHTHYL
76	CH ₃	H	H	CF ₃	H	-	4-MORPHOLINE	2-NAPHTHYL
77	CH ₃	H	H	SO ₂ CH ₃	H	-	4-MORPHOLINE	2-NAPHTHYL
78	CH ₃	H	H	SO ₂ N(CH ₃) ₂	H	-	4-MORPHOLINE	2-NAPHTHYL

TABLE 1 (CONTINUED)

CPD	R ¹	R ²	R ³	R ⁴	R ^{7*}	Z	Q1	Q2
79	CH ₃	H	H	H	H	-	4-MORPHOLINE	2-THIENYL
80	CH ₃	H	H	F	H	-	4-MORPHOLINE	2-THIENYL
81	CH ₃	H	H	Cl	H	-	4-MORPHOLINE	2-THIENYL
82	CH ₃	H	H	OCH ₃	H	-	4-MORPHOLINE	2-THIENYL
83	CH ₃	H	H	OCF ₃	H	-	4-MORPHOLINE	2-THIENYL
84	CH ₃	H	H	CF ₃	H	-	4-MORPHOLINE	2-THIENYL
85	CH ₃	H	H	SO ₂ CH ₃	H	-	4-MORPHOLINE	2-THIENYL
86	CH ₃	H	H	SO ₂ N(CH ₃) ₂	H	-	4-MORPHOLINE	2-THIENYL
87	CH ₃	H	H	H	H	-	4-MORPHOLINE	5-CHLORO-2-THIENYL
88	CH ₃	H	H	F	H	-	4-MORPHOLINE	5-CHLORO-2-THIENYL
89	CH ₃	H	H	Cl	H	-	4-MORPHOLINE	5-CHLORO-2-THIENYL
90	CH ₃	H	H	OCH ₃	H	-	4-MORPHOLINE	5-CHLORO-2-THIENYL
91	CH ₃	H	H	OCF ₃	H	-	4-MORPHOLINE	5-CHLORO-2-THIENYL
92	CH ₃	H	H	CF ₃	H	-	4-MORPHOLINE	5-CHLORO-2-THIENYL
93	CH ₃	H	H	SO ₂ CH ₃	H	-	4-MORPHOLINE	5-CHLORO-2-THIENYL
94	CH ₃	H	H	SO ₂ N(CH ₃) ₂	H	-	4-MORPHOLINE	5-CHLORO-2-THIENYL
95	CH ₃	H	H	H	H	-	4-MORPHOLINE	3,4,5-TRICHLORO-2-THIENYL
96	CH ₃	H	H	F	H	-	4-MORPHOLINE	3,4,5-TRICHLORO-2-THIENYL
97	CH ₃	H	H	Cl	H	-	4-MORPHOLINE	3,4,5-TRICHLORO-2-THIENYL
98	CH ₃	H	H	OCF ₃	H	-	4-MORPHOLINE	3,4,5-TRICHLORO-2-THIENYL

- 16 -

TABLE 1 (CONTINUED)

CPD	R ¹	R ²	R ³	R ⁴	R ^{7*}	Z	Q ¹	Q ²
99	CH ₃	H	H	OCF ₃	H	-	4-MORPHOLINE	3,4,5-TRICHLORO-2-THIENYL
100	CH ₃	H	H	CF ₃	H	-	4-MORPHOLINE	3,4,5-TRICHLORO-2-THIENYL
101	CH ₃	H	H	SO ₂ CH ₃	H	-	4-MORPHOLINE	3,4,5-TRICHLORO-2-THIENYL
102	CH ₃	H	H	SO ₂ N(CH ₃) ₂	H	-	4-MORPHOLINE	3,4,5-TRICHLORO-2-THIENYL
103	CH ₃	H	H	H	H	-	4-MORPHOLINE	2-FURANYL
104	CH ₃	H	H	F	H	-	4-MORPHOLINE	2-FURANYL
105	CH ₃	H	H	Cl	H	-	4-MORPHOLINE	2-FURANYL
106	CH ₃	H	H	OCH ₃	H	-	4-MORPHOLINE	2-FURANYL
107	CH ₃	H	H	OCF ₃	H	-	4-MORPHOLINE	2-FURANYL
108	CH ₃	H	H	CF ₃	H	-	4-MORPHOLINE	2-FURANYL
109	CH ₃	H	H	SO ₂ CH ₃	H	-	4-MORPHOLINE	2-FURANYL
110	CH ₃	H	H	SO ₂ N(CH ₃) ₂	H	-	4-MORPHOLINE	2-FURANYL
111	CH ₃	H	H	H	H	-	4-MORPHOLINE	5-CHLORO-2-FURANYL
112	CH ₃	H	H	F	H	-	4-MORPHOLINE	5-CHLORO-2-FURANYL
113	CH ₃	H	H	Cl	H	-	4-MORPHOLINE	5-CHLORO-2-FURANYL
114	CH ₃	H	H	OCH ₃	H	-	4-MORPHOLINE	5-CHLORO-2-FURANYL
115	CH ₃	H	H	OCF ₃	H	-	4-MORPHOLINE	5-CHLORO-2-FURANYL
116	CH ₃	H	H	CF ₃	H	-	4-MORPHOLINE	5-CHLORO-2-FURANYL
117	CH ₃	H	H	SO ₂ ClH ₃	H	-	4-MORPHOLINE	5-CHLORO-2-FURANYL
118	CH ₃	H	H	SO ₂ N(CH ₃) ₂	H	-	4-MORPHOLINE	5-CHLORO-2-FURANYL

- 17 -

TABLE I (CONTINUED)

CPD	R ¹	R ²	R ³	R ⁴	R ^{7*}	Z	Q ₁	Q ₂
119	CH ₃	H	H	H	H	-	4-MORPHOLINE	3-FURANYL
120	CH ₃	H	H	F	H	-	4-MORPHOLINE	3-FURANYL
121	CH ₃	H	H	Cl	H	-	4-MORPHOLINE	3-FURANYL
122	CH ₃	H	H	OCH ₃	H	-	4-MORPHOLINE	3-FURANYL
123	CH ₃	H	H	OCF ₃	H	-	4-MORPHOLINE	3-FURANYL
124	CH ₃	H	H	CF ₃	H	-	4-MORPHOLINE	3-FURANYL
125	CH ₃	H	H	SO ₂ CH ₃	H	-	4-MORPHOLINE	3-FURANYL
126	CH ₃	H	H	SO ₂ N(CH ₃) ₂	H	-	4-MORPHOLINE	3-FURANYL
127	CH ₃	H	H	H	H	-	4-MORPHOLINE	3-THIENYL
128	CH ₃	H	H	F	H	-	4-MORPHOLINE	3-THIENYL
129	CH ₃	H	H	Cl	H	-	4-MORPHOLINE	3-THIENYL
130	CH ₃	H	H	OCH ₃	H	-	4-MORPHOLINE	3-THIENYL
131	CH ₃	H	H	OCF ₃	H	-	4-MORPHOLINE	3-THIENYL
132	CH ₃	H	H	CF ₃	H	-	4-MORPHOLINE	3-THIENYL
133	CH ₃	H	H	SO ₂ CH ₃	H	-	4-MORPHOLINE	3-THIENYL
134	CH ₃	H	H	SO ₂ N(CH ₃) ₂	H	-	4-MORPHOLINE	3-THIENYL
135	CH ₃	H	H	H	H	-	1-PIPERIDINYL	2-CHLOROPHENYL
136	CH ₃	H	H	F	H	-	1-PIPERIDINYL	2-CHLOROPHENYL
137	CH ₃	H	H	Cl	H	-	1-PIPERIDINYL	2-CHLOROPHENYL
138	CH ₃	H	H	OCF ₃	H	-	1-PIPERIDINYL	2-CHLOROPHENYL

TABLE 1 (CONTINUED)

CPD	R ¹	R ²	R ³	R ⁴	R ^{7*}	Z	Q ₁	Q ₂
139	CH ₃	H	H	OCF ₃	H	-	1-PIPERIDINYL	2-CHLOROPHENYL
140	CH ₃	H	H	CF ₃	H	-	1-PIPERIDINYL	2-CHLOROPHENYL
141	CH ₃	H	H	SO ₂ CH ₃	H	-	1-PIPERIDINYL	2-CHLOROPHENYL
142	CH ₃	H	H	SO ₂ N(CH ₃) ₂	H	-	1-PIPERIDINYL	2-CHLOROPHENYL
143	CH ₃	H	H	H	H	-	1-PIPERIDINYL	2,3-DICHLOROPHENYL
144	CH ₃	H	H	F	H	-	1-PIPERIDINYL	2,3-DICHLOROPHENYL
145	CH ₃	H	H	Cl	H	-	1-PIPERIDINYL	2,3-DICHLOROPHENYL
146	CH ₃	H	H	OCH ₃	H	-	1-PIPERIDINYL	2,3-DICHLOROPHENYL
147	CH ₃	H	H	OCF ₃	H	-	1-PIPERIDINYL	2,3-DICHLOROPHENYL
148	CH ₃	H	H	CF ₃	H	-	1-PIPERIDINYL	2,3-DICHLOROPHENYL
149	CH ₃	H	H	SO ₂ CH ₃	H	-	1-PIPERIDINYL	2,3-DICHLOROPHENYL
150	CH ₃	H	H	SO ₂ N(CH ₃) ₂	H	-	1-PIPERIDINYL	2,3-DICHLOROPHENYL
151	CH ₃	H	H	H	H	-	1-PIPERIDINYL	1-NAPHTHYL
152	CH ₃	H	H	F	H	-	1-PIPERIDINYL	1-NAPHTHYL
153	CH ₃	H	H	Cl	H	-	1-PIPERIDINYL	1-NAPHTHYL
154	CH ₃	H	H	OCH ₃	H	-	1-PIPERIDINYL	1-NAPHTHYL
155	CH ₃	H	H	OCF ₃	H	-	1-PIPERIDINYL	1-NAPHTHYL
156	CH ₃	H	H	CF ₃	H	-	1-PIPERIDINYL	1-NAPHTHYL
157	CH ₃	H	H	SO ₂ CH ₃	H	-	1-PIPERIDINYL	1-NAPHTHYL

- 19 -

TABLE 1 (CONTINUED)

CPD	R ¹	R ²	R ³	R ⁴	R ^{7*}	Z	Q ₁	Q ₂
158	CH ₃	H	H	SO ₂ N(CH ₃) ₂	H	-	1-PIPERIDINYL	1-NAPHTHYL
159	CH ₃	H	H	H	H	-	1-PIPERIDINYL	2-NAPHTHYL
160	CH ₃	H	H	F	H	-	1-PIPERIDINYL	2-NAPHTHYL
161	CH ₃	H	H	Cl	H	-	1-PIPERIDINYL	2-NAPHTHYL
162	CH ₃	H	H	OCH ₃	H	-	1-PIPERIDINYL	2-NAPHTHYL
163	CH ₃	H	H	OCF ₃	H	-	1-PIPERIDINYL	2-NAPHTHYL
164	CH ₃	H	H	CF ₃	H	-	1-PIPERIDINYL	2-NAPHTHYL
165	CH ₃	H	H	SO ₂ CH ₃	H	-	1-PIPERIDINYL	2-NAPHTHYL
166	CH ₃	H	H	SO ₂ N(CH ₃) ₂	H	-	1-PIPERIDINYL	2-NAPHTHYL
167	CH ₃	H	H	H	H	-	1-PIPERIDINYL	2-THIENYL
168	CH ₃	H	H	F	H	-	1-PIPERIDINYL	2-THIENYL
169	CH ₃	H	H	Cl	H	-	1-PIPERIDINYL	2-THIENYL
170	CH ₃	H	H	OCH ₃	H	-	1-PIPERIDINYL	2-THIENYL
171	CH ₃	H	H	OCF ₃	H	-	1-PIPERIDINYL	2-THIENYL
172	CH ₃	H	H	CF ₃	H	-	1-PIPERIDINYL	2-THIENYL
173	CH ₃	H	H	SO ₂ CH ₃	H	-	1-PIPERIDINYL	2-THIENYL
174	CH ₃	H	H	SO ₂ N(CH ₃) ₂	H	-	1-PIPERIDINYL	2-THIENYL
175	CH ₃	H	H	H	H	-	1-PIPERIDINYL	5-CHLORO-2-THIENYL
176	CH ₃	H	H	F	H	-	1-PIPERIDINYL	5-CHLORO-2-THIENYL
177	CH ₃	H	H	Cl	H	-	1-PIPERIDINYL	5-CHLORO-2-THIENYL

- 20 -

TABLE I (CONTINUED)

CPD	R ¹	R ²	R ³	R ⁴	R ^{7*}	Z	Q ₁	Q ₂
178	CH ₃	H	H	OCH ₃	H	-	1-PIPERIDINYL	5-CHLORO-2-THIENYL
179	CH ₃	H	H	OCF ₃	H	-	1-PIPERIDINYL	5-CHLORO-2-THIENYL
180	CH ₃	H	H	CF ₃	H	-	1-PIPERIDINYL	5-CHLORO-2-THIENYL
181	CH ₃	H	H	SO ₂ CH ₃	H	-	1-PIPERIDINYL	5-CHLORO-2-THIENYL
182	CH ₃	H	H	SO ₂ N(CH ₃) ₂	H	-	1-PIPERIDINYL	5-CHLORO-2-THIENYL
183	CH ₃	H	H	H	H	-	1-PIPERIDINYL	3,4,5-TRICHLORO-2-THIENYL
184	CH ₃	H	H	F	H	-	1-PIPERIDINYL	3,4,5-TRICHLORO-2-THIENYL
185	CH ₃	H	H	Cl	H	-	1-PIPERIDINYL	3,4,5-TRICHLORO-2-THIENYL
186	CH ₃	H	H	OCH ₃	H	-	1-PIPERIDINYL	3,4,5-TRICHLORO-2-THIENYL
187	CH ₃	H	H	OCF ₃	H	-	1-PIPERIDINYL	3,4,5-TRICHLORO-2-THIENYL
188	CH ₃	H	H	CF ₃	H	-	1-PIPERIDINYL	3,4,5-TRICHLORO-2-THIENYL
189	CH ₃	H	H	SO ₂ CH ₃	H	-	1-PIPERIDINYL	3,4,5-TRICHLORO-2-THIENYL
190	CH ₃	H	H	SO ₂ N(CH ₃) ₂	H	-	1-PIPERIDINYL	3,4,5-TRICHLORO-2-THIENYL
191	CH ₃	H	H	H	H	-	1-PIPERIDINYL	2-FURANYL
192	CH ₃	H	H	F	H	-	1-PIPERIDINYL	2-FURANYL
193	CH ₃	H	H	Cl	H	-	1-PIPERIDINYL	2-FURANYL
194	CH ₃	H	H	OCH ₃	H	-	1-PIPERIDINYL	2-FURANYL
195	CH ₃	H	H	OCF ₃	H	-	1-PIPERIDINYL	2-FURANYL
196	CH ₃	H	H	CF ₃	H	-	1-PIPERIDINYL	2-FURANYL
197	CH ₃	H	H	SO ₂ CH ₃	H	-	1-PIPERIDINYL	2-FURANYL

TABLE 1 (CONTINUED)

CPD	R ¹	R ²	R ³	R ⁴	R ^{7*}	Z	Q ₁	Q ₂
198	CH ₃	H	H	SO ₂ N(CH ₃) ₂	H	-	1-PIPERIDINYL	2-FURANYL
199	CH ₃	H	H	H	H	-	1-PIPERIDINYL	3-FURANYL
200	CH ₃	H	H	F	H	-	1-PIPERIDINYL	3-FURANYL
201	CH ₃	H	H	Cl	H	-	1-PIPERIDINYL	3-FURANYL
202	CH ₃	H	H	OCH ₃	H	-	1-PIPERIDINYL	3-FURANYL
203	CH ₃	H	H	OCF ₃	H	-	1-PIPERIDINYL	3-FURANYL
204	CH ₃	H	H	CF ₃	H	-	1-PIPERIDINYL	3-FURANYL
205	CH ₃	H	H	SO ₂ CH ₃	H	-	1-PIPERIDINYL	3-FURANYL
206	CH ₃	H	H	SO ₂ N(CH ₃) ₂	H	-	1-PIPERIDINYL	3-FURANYL
207	CH ₃	H	H	H	H	-	1-PIPERIDINYL	5-CHLORO-2-FURANYL
208	CH ₃	H	H	F	H	-	1-PIPERIDINYL	5-CHLORO-2-FURANYL
209	CH ₃	H	H	Cl	H	-	1-PIPERIDINYL	5-CHLORO-2-FURANYL
210	CH ₃	H	H	OCH ₃	H	-	1-PIPERIDINYL	5-CHLORO-2-FURANYL
211	CH ₃	H	H	OCF ₃	H	-	1-PIPERIDINYL	5-CHLORO-2-FURANYL
212	CH ₃	H	H	CF ₃	H	-	1-PIPERIDINYL	5-CHLORO-2-FURANYL
213	CH ₃	H	H	SO ₂ CH ₃	H	-	1-PIPERIDINYL	5-CHLORO-2-FURANYL
214	CH ₃	H	H	SO ₂ N(CH ₃) ₂	H	-	1-PIPERIDINYL	5-CHLORO-2-FURANYL
215	CH ₃	H	H	H	H	-	1-PIPERIDINYL	3-THIENYL
216	CH ₃	H	H	F	H	-	1-PIPERIDINYL	3-THIENYL
217	CH ₃	H	H	Cl	H	-	1-PIPERIDINYL	3-THIENYL

- 22 -

TABLE I (CONTINUED)

CPD	R ¹	R ²	R ³	R ⁴	R ^{7*}	Z	Q ₁	Q ₂
218	CH ₃	H	H	OCH ₃	H	-	1-PIPERIDINYL	3-THIENYL
219	CH ₃	H	H	OCF ₃	H	-	1-PIPERIDINYL	3-THIENYL
220	CH ₃	H	H	CF ₃	H	-	1-PIPERIDINYL	3-THIENYL
221	CH ₃	H	H	SO ₂ CH ₃	H	-	1-PIPERIDINYL	3-THIENYL
222	H	H	H	SO ₂ N(CH ₃) ₂	H	-	1-PIPERIDINYL	3-THIENYL
223	H	H	H	Cl	H	-	(CH ₃) ₃ N ⁺	2-CHLOROPHENYL
224	H	H	H	OCH ₃	H	-	(CH ₃) ₃ N ⁺	2,3-DICHLOROPHENYL
225	H	H	H	Cl	H	-	2-PYRIDINYL	2-CHLOROPHENYL
226	H	H	H	OCH ₃	H	-	2-PYRIDINYL	2,3-DICHLOROPHENYL
227	H	H	H	Cl	H	-	1-PYRROLIDINYL	9-ANTHRACYL
228	H	H	H	OCH ₃	H	-	1PYRROLIDINYL	9-ANTHRACYL
229	H	H	H	Cl	H	-	2-PYRIDINYL	2-CHLOROPHENYL
230	H	H	H	OCH ₃	H	-	2-PYRIDINYL	2,3-DICHLOROPHENYL
231	H	H	H	Cl	H	-	2-PYRROLIDINYL	9-ANTHRACYL
232	H	H	H	OCH ₃	H	-	2-PYRROLIDINYL	9-ANTHRACYL
233	H	H	H	Cl	H	-	1-PIPERAZINYL	2-CHLOROPHENYL
234	H	H	H	OCH ₃	H	-	2-PIPERAZINYL	2,3-DICHLOROPHENYL
235	H	H	H	Cl	H	-	PHENYL	9-ANTHRACYL
236	CH ₃	H	H	OCH ₃	H	-	PHENYL	2-CHLOROPHENYL
237	CH ₃	H	H	Cl	H	-	PHENYL	2,3-DICHLOROPHENYL

TABLE 1 (CONTINUED)

CPD	R ¹	R ²	R ³	R ⁴	R ^{7*}	Z	Q ₁	Q ₂
238	CH ₃	H	H	OCH ₃	H	-	2-CHLOROPHENYL	9-ANTHRACYL
239	CH ₃	H	H	Cl	H	-	2,3-DICHLOROPHENYL	2-CHLOROPHENYL
240	CH ₃	H	H	OCH ₃	H	-	2-THIENYL	2,3-DICHLOROPHENYL
241	CH ₃	H	H	Cl	H	-	3-THIENYL	2-CHLOROPHENYL
242	CH ₃	H	H	OCH ₃	H	CO	1-PIPERIDINYL	2-CHLOROPHENYL
243	CH ₃	H	H	Cl	H	CO	1-PIPERIDINYL	2,3-DICHLOROPHENYL
244	CH ₃	H	H	OCH ₃	H	CO	1-PIPERIDINYL	9-ANTHRACYL
245	CH ₃	H	H	Cl	H	CO	1-PIPERIDINYL	2-THIENYL
246	CH ₃	H	H	OCH ₃	H	CO	1-PIPERIDINYL	3-THIENYL
247	CH ₃	H	H	Cl	H	CO	1-PIPERIDINYL	2-FURANYL
248	CH ₃	H	H	OCH ₃	H	CO	1-PIPERIDINYL	3-FURANYL
249	CH ₃	H	H	Cl	H	CO	1-PIPERIDINYL	1-NAPHTHYL
250	CH ₃	H	H	OCH ₃	H	CO	1-PIPERIDINYL	2-NAPHTHYL
251	CH ₃	H	H	Cl	H	CO	1-PYRROLIDINYL	2-CHLOROPHENYL
252	CH ₃	H	H	OCH ₃	H	CO	1-PYRROLIDINYL	2,3-DICHLOROPHENYL
253	CH ₃	H	H	Cl	H	CO	1-PYRROLIDINYL	9-ANTHRACYL
254	CH ₃	H	H	OCH ₃	H	CO	1-PYRROLIDINYL	2-THIENYL
255	CH ₃	H	H	Cl	H	CO	1-PYRROLIDINYL	3-THIENYL
256	CH ₃	H	H	OCH ₃	H	CO	1-PYRROLIDINYL	2-FURANYL
257	CH ₃	H	H	H	H	CO	4-MORPHOLINE	1-NAPHTHYL

- 24 -

TABLE I (CONTINUED)

CPD	R1	R2	R3	R4	R7*	Z	Q1	Q2
258	CH3	H	H	OCH3	H	CO	4-MORPHOLINE	2,5-DICHLOROPHENYL
259	CH3	H	H	OCH3	H	CO	4-MORPHOLINE	2,3-DICHLOROPHENYL
260	CH3	H	H	OCH3	H	CO	4-MORPHOLINE	2-CHLORO-4-FLUOROPHENYL
261	CH3	H	H	OCH3	H	CO	4-MORPHOLINE	3-CHLOROPHENYL
262	CH3	H	H	H	H	-	COOCH3	1-NAPHTHYL
263	CH3	H	H	H	H(m=2)	-	4-MORPHOLINE	1-NAPHTHYL
264	CH3	H	H	OCH3	H(m=2)	-	4-MORPHOLINE	2,3-DICHLOROPHENYL
265	CH3	H	H	H	H	-	4-MORPHOLINE	2-CHLOROPHENYL
266	CH3	H	H	OCH3	H(m=2)	-	4-MORPHOLINE	1-NAPHTHYL
267	CH3	H	H	OCH3	H(m=2)	-	4-MORPHOLINE	2-CHLOROPHENYL
268	CH3	H	H	H	H(m=2)	-	4-MORPHOLINE	2-CHLOROPHENYL

- 25 -

Elemental analysis was conducted on several of the compounds listed above and the results are shown below.

TABLE 2

ELEMENTAL ANALYSIS									
CPD	FORMULA	CALCULATED			FOUND			C	N
		C	H	N	C	H	N		
31	C ₂₃ H ₂₃ ClN ₂ O ₄	64.71	5.43	6.56	64.78	5.69	6.42		
63	C ₂₅ H ₂₃ ClN ₂ O ₂	71.33	5.99	6.65	71.23	6.99	6.57		
258	C ₂₃ H ₂₂ Cl ₂ N ₂ O ₄	59.88	4.81	6.07	59.56	4.86	6.09		
259	C ₂₃ H ₂₂ Cl ₂ N ₂ O ₄	59.88	4.81	6.07	59.25	4.89	5.81		
260	C ₂₃ H ₂₂ ClFN ₂ O ₄	62.09	4.98	6.30	62.05	5.04	6.53		
261	C ₂₃ H ₂₃ ClN ₂ O ₄	64.71	5.43	6.56	63.36	5.29	6.47		
263	C ₂₆ H ₂₇ ClN ₂ O ₂	71.80	6.26	6.44	71.64	6.36	6.15		

- 26 -

The preferred compounds are realized when:

- R¹ is H, lower alkyl, or lower fluorinated alkyl;
 R²⁻⁴ is independently H, lower alkyl, OR¹, halogen, or lower
 fluorinated alkyl;
 5 R⁷ is H, or lower alkyl; and
 Q₁ is morpholine, piperazine, piperidine, or pyrrolidine.

The most preferred compounds are realized when:

- 10 R¹ is lower alkyl;
 R²⁻⁴ is independently is H, or OR¹;
 R⁷ is H;
 Q₁ is morpholine;
 m is 2; and
 Z is a bond.

15

Specific compounds are:

- 2-[1-(2-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-1-
 [morpholin-4-yl]ethanone;
 20 2-Methyl-3-(morpholin-4-yl)methyl-1-(1-naphthoyl)-1H-indole;
 2-Methyl-1-(1-naphthoyl)-1H-indol-3-ylacetic acid, methyl ester;
 1-(2-Chlorobenzoyl)-5-methoxy-2-methyl-3-(morpholin-4-ylmethyl)-
 25 1H-indole;
 1-(2,3-Dichlorobenzoyl)-2-methyl-3-(morpholin-4-ylmethyl)-1H-
 indole;
 1-(2,3-Dichlorobenzoyl)-5-methoxy-2-methyl-3-(morpholin-4-
 ylmethyl)-1H-indole;
 30 1-(1-Naphthoyl)-5-methoxy-2-methyl-3-(morpholin-4-ylmethyl)-1H-
 indole;
 1-(2,3-Dichlorobenzoyl)-5-methoxy-2-methyl-3-(2-(morpholin-4-
 yl)ethyl)-1H-indole;

- 27 -

1-(2-Chlorobenzoyl)-2-methyl-3-(morpholin-4-ylmethyl)-1*H*-indole:

1-(1-Naphthoyl)-5-Methoxy-2-methyl-3-(2-(morpholin-4-yl)ethyl)-1*H*-indole;

5 1-(2-Chlorobenzoyl)-5-methoxy-2-methyl-3-(2-(morpholin-4-yl)ethyl)-1*H*-indole; and

1-(2-Chlorobenzoyl)-2-methyl-3-(2-(morpholin-4-yl)ethyl)-1*H*-indole.

Utilities

10 The ability of the compounds of formula I to mimic the actions of the cannabinoids makes them useful for preventing or reversing the symptoms that can be treated with cannabis, some of its derivatives and synthetic cannabinoids in a human subject. Thus, compounds of formula I are useful to treat, prevent, or ameliorate in
15 mammals and especially in humans:

- 1- various ocular disorders such as glaucoma.
- 2- pulmonary disorders including diseases such as asthma, chronic bronchitis and related airway diseases.
- 20 3- allergies and allergic reactions such as allergic rhinitis, contact dermatitis, allergic conjunctivitis and the like.
- 4- inflammation such as arthritis or inflammatory bowel disease.
- 5- pain.
- 6- disorders of the immune system such as lupus, AIDS, etc.
- 25 7- allograft rejection.
- 8- central nervous system diseases such as Tourette's syndrome, Parkinson's disease, Huntingdon's disease, epilepsy, various psychotic afflictions such as depression, manic depression, etc.
- 9- vomiting, and nausea and vertigo, especially in the case of
30 chemotherapy patients.

- 28 -

Dose Ranges

5 The magnitude of therapeutic dose of a compound of Formula I will, of course, vary with the nature of the severity of the condition to be treated and with the particular compound of Formula I and its route of administration and vary upon the clinician's judgment. It will also vary according to the age, weight and response of the individual patient. An effective dosage amount of the active component can thus be determined by the clinician after a consideration of all the
10 criteria and using is best judgment on the patient's behalf.

An ophthalmic preparation for ocular administration comprising 0.001-1% by weight solutions or suspensions of the compounds of Formula I in an acceptable ophthalmic formulation may be used.

15

Pharmaceutical Compositions

Any suitable route of administration may be employed for providing a mammal, especially a human with an effective dosage of a compound of the present invention. For example, oral, parenteral and
20 topical may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like.

The pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a
25 pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic bases or acids and organic bases or acids.

30 The compositions include compositions suitable for oral, parenteral and ocular (ophthalmic). They may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy.

In practical use, the compounds of Formula I can be combined as the active ingredient in intimate admixture with a

- 29 -

pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration. In preparing the compositions for oral dosage form, any of the usual
5 pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants,
10 binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, capsules and tablets, with the solid oral preparations being preferred over the liquid preparations. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid
15 pharmaceutical carriers are obviously employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques.

Pharmaceutical compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount
20 of the active ingredient, as a powder or granules or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion or a water-in-oil liquid emulsion. Such compositions may be prepared by any of the methods of pharmacy but all methods include the step of bringing into association the active ingredient with the carrier
25 which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation. For example, a tablet may be prepared by compression or
30 molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by

- 30 -

molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Desirably, each tablet contains from about 1 mg to about 500 mg of the active ingredient and each cachet or capsule contains from about 1 to about 500 mg of the active ingredient.

Combinations with Other Drugs

In addition to the compounds of Formula I, the pharmaceutical compositions of the present invention can also contain other active ingredients or prodrugs thereof. These other active species may be beta-blockers such as timolol, topical carbonic anhydrase inhibitors such as Dorzolamide, systemic carbonic anhydrase inhibitors such as acetolamide, cholinergic agents such as pilocarpine and its derivatives, prostaglandin F receptor agonists such as Latanoprost, ajmaline and its derivatives, b₂ adrenergic agonists such as epinephrine, glutamate antagonists, aminosteroids, diuretics, and any other compound used alone or in combination in the treatment of glaucoma. The weight ratio of the compound of the Formula I to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used. Thus, for example, when a compound of the Formula I is combined with a b-blockers, a carbonic anhydrase inhibitor, a pilocarpine derivative or a prostaglandin agonist, the weight ratio of the compound of the Formula I to the other drug will generally range from about 1000:1 to about 1:1000, preferably about 200:1 to about 1:200. Combinations of a compound of the Formula I and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.

Methods of Synthesis


Compounds of the present invention can be prepared according to the following non-limiting methods. Temperatures are in degrees Celsius.

- 31 -

Method A

The starting indoles used are either commercially available or prepared from an appropriate hydrazine II and a properly substituted aldehyde or ketone III as described in U.S. patent 3,161,654 (incorporated herein). The indole IV obtained is then treated with an acyl chloride or bromide of a properly substituted Q₂ and a base to afford the desired indole I. When Z-Q¹ is an ester, it can be hydrolysed to the desired acid Ia with a base such as 1N NaOH in a protic solvent such as MeOH-H₂O.

METHOD A




- 32 -

Method B

The acids Ia can be converted to a variety of esters Ib by dissolution in the appropriate lower alkyl alcohol with a strong acid such as 10% H₂SO₄ and heated between 60-90° C for 3-12h (Fischer conditions).

METHOD B

Method C


Acids Ia are treated with a chlorinating agent such as oxalyl chloride in an inert solvent (methylene chloride, dichloroethane, etc.). The resulting acyl halide is then treated with amines or thiols in the presence of a base (excess amine, Et₃N, etc.) to afford the corresponding amide Ic or thiol ester Id.

25

30


- 33 -

METHOD C

Method D

20 The primary amides of 1c in an inert solvent such as THF, Et₂O, etc. and a base such as pyridine are treated with a dehydrating agent such as trifluoroacetic anhydride at 0° C to afford the nitrile 1e.

METHOD D



- 34 -


Method E

Acids Ia are treated with borane according to the literature (J.Org. Chem. 1973, **38**, 2786) to afford the alcohols If.

5

METHOD E

10



15

20

25

30


- 35 -

Method F

Compounds of type If can be converted to their mesylate or tosylate in an inert solvent such as CH_2Cl_2 in the presence of a base such as Et_3N and then reacted with various nucleophiles such as

5 alcohols, thiols and amines to produce compounds Ig, Ih and Ii.

METHOD F




- 36 -

Method G

When compounds of type If are subjected to Swern oxidation (J. Org. Chem. 1978, **43**, 2480), with PCC (Tetrahedron Lett. 1975, 2647) or other oxidizing agents, aldehyde Ij is obtained.

5

METHOD G



- 37 -

Method H

Compounds of type Ih can be reduced to the alkyl chain by reaction with Raney-Nickel in a protic solvent such as ethanol to afford Ik, which can also be prepared by a Fischer indole synthesis starting with an appropriate hydrazine II and a ketone or aldehyde IIIa under acidic conditions. Compound Ih can be oxidized to the sulfoxide or sulfone using for example H₂O₂ or MCPBA to give Il.

10


METHOD H

15

20

25


30



- 38 -

Method I

An indole of type V can be deprotonated with a strong base such as MeMgBr, treated with ZnCl₂ to exchange the metal when necessary, and an alkylating agent or (other electrophile) added to the mixture to yield compound of type IVa. This in turn according to method A can be converted to a compound of type I.



- 39 -

Method J

An indole of type VI can be treated according to method A to yield VII which can be converted to Im with an amine in presence of a reducing agent such as NaBH₃CN.

5


10

15

20

25

30




- 40 -

Method K

A carboxylic acid of type VIII can be coupled with various amines in an inert solvent such as CH_2Cl_2 using DCC or the like to yield IX, which can then be converted to In according to method A.

5



15

20

25

30

The invention will now be illustrated by the following non-limiting examples (Note: The examples in Table 1, above, that are not illustrated can be made by substantially similar procedures as discussed below) in which, unless stated otherwise:

- (i) all operations are carried out at room or ambient temperature, that is, at a temperature in the range 18-25°C:

- 41 -

- (ii) evaporation of solvent is carried out using a rotary evaporator under reduced pressure (600-4000 pascals: 4.5-30 mm Hg) with a bath temperature of up to 60°C;
- 5 (iii) the course of reactions is followed by thin layer chromatography (TLC) and reaction times are given for illustration only;
- 10 (iv) melting points are uncorrected and 'd' indicates decomposition; the melting points given are those obtained for the materials prepared as described; polymorphism may result in isolation of materials with different melting points in some preparations;
- 15 (v) the structure and purity of all final products are assured by at least one of the following techniques: TLC, mass spectrometry, nuclear magnetic resonance (NMR) spectrometry, or microanalytical data;
- 20 (vi) yields are given for illustration only;
- (vii) when given, NMR data are in the form of delta (δ) values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 300 MHz or 400 MHz using the indicated solvent: conventional abbreviations used for signal shape are: s. singlet; d. doublet; t. triplet; m. multiplet; br. broad; etc.; in addition "Ar" signifies an aromatic signal;
- 25 (viii) chemical symbols have their usual meanings; the following abbreviations have also been used: v (volume), w (weight), b.p. (boiling point), m.p. (melting point), L (liter(s)), mL
- 30

- 42 -

(milliliters), g (gram(s)), mg (milligram(s)), mol (moles),
mmol (millimoles), eq. (equivalent(s)).

EXAMPLES

5 Examples provided are intended to assist in a further
understanding of the invention. Particular materials employed, species
and conditions are intended to be further illustrative of the invention
and not limitative of the reasonable scope thereof.

10

EXAMPLE 1

2-[1-(2-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-1-
[morpholin-4-yl]ethanone

15 Step 1: 2-[5-methoxy-2-methyl-1H-indol-3-yl]-1-[morpholin-4-yl]-
ethanone

To 5-methoxy-2-methyl-3-indoleacetic acid (0.665g; 3.03
mmol) in 6 mL of THF was added DCC (0.661g; 3.2 mmol). After 2 h
of stirring, morpholine (1 mL; 11.4 mmol) was added and stirred for
20 another 1 h. The reaction mixture was filtered and the solvent removed.
Chromatography on silica gel (eluted with EtOAc) yielded 0.585g
(64%) of the title compound.

¹H NMR (CDCl₃, 400 MHz) δ 2.30 (s, 3H), 3.38 (m, 4H), 3.60 (m,
25 4H), 3.70 (s, 2H), 3.82 (s, 3H), 6.7 (m, 1H), 6.93 (s, 1H), 7.09 (d, 1H)
and 7.97 (s, 1H).

30 Step 2: 2-[1-(2-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-
yl]-1-[morpholin-4-yl]ethanone

To the amide (0.506g : 1.75 mmol) from step 1 in 10 mL
of THF and 0.9 mL of HMPA cooled to -78° C was added KHMDS 0.5
M (3.5 mL; 1.75 mmol) dropwise. The temperature was raised to -22°
C for 30 min and brought back to -78° C. Then 2-chlorobenzoyl

- 43 -

chloride (0.33 mL; 2.61 mmol) was added and left stirring for 16 hr. It was then poured into cold water-EtOAc (50 mL). The organic phase was washed with H₂O (2 X 15 mL) and brine. The organic phase was dried over Na₂SO₄ and the solvent removed. Chromatography on silica gel (eluted with EtOAc) followed by a swish in CH₂Cl₂ (hot) - hexane afforded 0.462g (78%) of the title compound.

¹H NMR (CDCl₃, 400 MHz) δ 2.22 (s, 3H), 3.44 (m, 4H), 3.61 (s, 4H), 3.66 (s, 2H), 3.80 (s, 3H), 6.67-6.70 (dd, 1H), 6.96 (d, 1H), 7.10 (d, 1H), and 7.39-7.50 (m, 4H).

EXAMPLE 2

2-Methyl-3-(morpholin-4-yl)methyl-1-(1-naphthoyl)-1H-indole

Step 1: 3-Formyl-2-methyl-1-(1-naphthoyl)-1H-indole

To 3-formyl-2-methylindole (4.30g; 27.0 mmol) in 70 mL of DMF at r.t. was added NaH 80% (0.861 mg). After 30 min of stirring the solution was cooled to 0° C and a solution of 1-naphthoyl chloride (5.04g, 29.3 mmol) in 10 mL of DMF was added dropwise. The mixture was left stirring for 16h at r.t. and poured into cold water-EtOAc (100mL). The organic phase was washed with H₂O (2 X 25 mL) and brine. The organic phase was dried over Na₂SO₄ and the solvent removed. Chromatography on silica gel (eluted with 10% EtOAc in toluene) yielded 1.70g (20%) of the title compound.

¹H NMR (CDCl₃, 400 MHz) δ 2.64 (s, 3H), 6.95 (d, 1H), 7.04 (t, 1H), 7.10-7.30 (m, 1H), 7.51 (m, 1H), 7.59 (m, 3H), 7.96 (m, 1H), 8.11 (d, 1H) and 10.34 (s, 1H).

- 44 -

Step 2: 2-Methyl-3-(morpholin-4-yl)methyl-1-(1-naphthoyl)-1H-indole

To the aldehyde (0.118g ; 0.38 mmol) from step 1 and morpholine hydrochloride (0.99g; 3.8 mmol) in 10 mL of MeOH was added NaBH₃CN (0.057g; 0.91 mmol) and the mixture was left stirring for 16h at r.t. Another 60 mg of NaBH₃CN was added and left stirring 8 h. The reaction was then poured into H₂O-EtOAc (20 mL- 50 mL) and saturated with NaCl. The organic extracts were washed with brine and dry over Na₂SO₄. The solvent was removed and the crude product purified by chromatography on silica gel (eluted with 10% → 30% EtOAc in toluene) to yield 0.99g (68%) of the title compound.

¹H NMR (CDCl₃, 400 MHz) δ 2.18 (s, 3H), 2.46 (m, 4H), 3.59 (s, 2H), 3.67 (m, 4H), 7.02 (t, 1H), 7.20 (m, 3H), 7.40-7.55 (m, 2H) and 8.04 (d, 1H).

EXAMPLE 3

20 2-Methyl-1-(1-naphthoyl)-1H-indol-3-ylacetic acid, methyl ester

Step 1: 2-Methyl-1H-indol-3-ylacetic acid, methyl ester.

To 2-methyl indole (1.69 g; 12.9 mmol) in 10 mL of THF at 0° C was added MeMgBr 1.4M (12.9 mmol). After 30 min at 0° C. ZnCl₂ 1M (12.9 mL; 12.9 mmol) in THF was added and the reaction stirred for an other 30 min at r.t. Methyl bromoacetate (1.4 mL; 14.7 mmol) was added dropwise and left stirring for 48 h. The mixture was poured into aqueous NaHCO₃, extracted with EtOAc (3 X 25 mL) and the combined organic extracts were washed with brine. The solution was dried over Na₂SO₄ and the solvent removed. Chromatography on silica gel (eluted with 5% EtOAc in hexane) yielded 1.13g (43%) of the title compound.

- 45 -

¹H NMR (CDCl₃, 400 MHz) δ 2.39 (s, 3H), 3.64 (s, 3H), 3.68 (s, 2H), 7.05-7.13 (m, 2H), 7.22-7.26 (m, 1H), 7.49-7.52 (m, 1H) and 7.82 (s, 1H).

5 Step 2: 2-Methyl-1-(1-naphthoyl)-1H-indol-3-ylacetic acid, methyl ester

 The compound of step 1 (1.13g; 5.56 mmol) in 6 mL of DMF was treated with NaH 80% (0.18g; 5.99 mmol) at 25° C. After 30 min a solution of 1-naphthoyl chloride in 5 mL of DMF was added
10 dropwise. The reaction mixture was left stirring for 16h and poured into cold water-EtOAc. The organic phase was washed with H₂O (2 X 15 mL) and brine, dried over Na₂SO₄ and the solvent removed.

 Chromatography on silica gel (eluted with 2% EtOAc in toluene) yielded 0.86g (43%) of the title compound.
15 ¹H NMR (CDCl₃, 400 MHz) Δ 2.20 (s, 3H), 3.67 (s, 3H), 7.0 (m, 1H), 7.10-7.26 (m, 3H), 7.45-7.60 (m, 5H), 7.95 (m, 1H) AND 8.07 (m, 3H).

 High Resolution Mass Spectra results were: Formula (C₂₃H₁₉NO₃+H⁺); Calculated (358.14415); Found (358.14432)
20

25

30

- 46 -

EXAMPLE 4

5 1-(2,3-Dichlorobenzoyl)-5-methoxy-2-methyl-3-(2-(morpholin-4-yl)ethyl)-1H-indole

Step 1: 5-Methoxy-2-methyl-3-(2-(morpholin-4-yl)ethyl)-1H-indole

10 To 5-methoxy-2-methyl-1H-indole (5.00g ; 31.0mmol) in 30 mL of dry THF at 0°C was added dropwise MeMgBr (3.0M in Et₂O ; 11.4mL ; 34.2mmol). The solution was stirred 30 min at r.t. after which ZnCl₂ (0.5M in THF ; 64mL ; 32mmol) was added. The mixture was stirred at r.t., after 1h, N-(2-iodoethyl)morpholine (14.41g :
15 51.5mmol) was added. The final mixture was stirred at r.t. overnight. The mixture was poured in saturated NaHCO₃ (100mL), extracted with EtOAc (2x100mL). The organic phase was washed with brine (100mL), dried over Na₂SO₄, filtered, concentrated and flash chromatographed (Silica gel ; EtOAc / Ace O to 10%) to yield 587mg (7%) of the title
20 compound.

¹NMR (CDCl₃, 400MHz) δ 2.36 (s, 3H), 2.64 (bs, 6H), 2.92 (bs, 2H), 3.83 (bd, 4H), 3.85 (s, 3H), 6.76 (dd, 1H), 6.97 (d, 1H), 7.15 (d, 2H), 7.68 (bs, NH).

25

Step 2: 1-(2,3-Dichlorobenzoyl)-5-methoxy-2-methyl-3-(2-(morpholin-4-yl)ethyl)-1H-indole

30 To 5-methoxy-2-methyl-3-(2-(morpholin-4-yl)ethyl)-1H-indole (311mg ; 1.13mmol) in 10 mL dry THF at -78°C was added HMPA (590μL ; 3.39mmol), then dropwise KHMDS (0.5M in Tol ; 2.5mL : 1.25mmol). The solution was stirred 30 min at -22°C then cooled to -78°C after which 2,3-dichlorobenzoyl chloride (361mg ; 1.72mmol) was added. The final mixture was allowed to reach r.t. slowly then

- 47 -

stirred 1h. The mixture was poored in saturated NaHCO_3 (25mL),
extracted with EtOAc (2x50mL). The organic phase was washed with
brine (50mL), dried over Na_2SO_4 , filtered, concentrated and flash
chromatographed (Silica gel ; EtOAc) to yield 503mg (99%) of the title
5 compound.

^1NMR (CDCl_3 , 400MHz) δ 2.12 (s, 3H), 2.52 (m, 6H), 2.79 (t, 2H), 3.74
(t, 4H), 3.82 (s, 3H), 6.71 (dd, 1H), 6.91 (d, 1H), 7.34 (m, 3H), 7.61
(dd, 1H).

10 Elemental analysis for $\text{C}_{23}\text{H}_{24}\text{Cl}_2\text{N}_2\text{O}_3 \cdot \text{HCl}$, calcd: C: 57.1, H: 5.21, N:
5.79; found: C: 57.18, H: 5.26, N: 5.70.

15

20


25

30

- 48 -

WHAT IS CLAIMED IS:

1. A compound of the structural formula I:



I

pharmaceutically acceptable salts thereof, or diastereomers, or enantiomers or mixtures thereof,

15 wherein:

R^1 is H, lower alkyl, aryl, benzyl, or lower fluorinated alkyl;

R^{2-4} is independently, H, lower alkyl, lower fluorinated alkyl, halogen, NO_2 , CN, $-(\text{CR}^7_2)_m\text{-OR}^1$, $-(\text{CR}^7_2)_m\text{-S(O)}_n\text{R}^6$,
20 or $-(\text{CR}^7_2)_m\text{-R}^6$;

R^5 is H, lower alkyl, aryl, or benzyl;

R^6 is lower alkyl, aryl, benzyl, or $\text{N(R}^5)_2$;

R^7 is H, or lower alkyl;

R^8 is R^7 , lower fluorinated alkyl, halogen, OR^7 , or lower alkyl
25 thio;

R^9 is R^7 , lower fluorinated alkyl, halogen, OR^7 , or lower alkyl
thio;

Q_1 is H, OR^7 , CHO, CN, CO_2R^7 , C(O)SR^7 , $\text{S(O)}_n\text{R}^6$, HET or
30 $\text{N(R}^7)_2$, wherein two R^7 groups may be joined to form a pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine ring and their quaternary methyl ammonium salts;

- 49 -

Q₂ is phenyl, naphthyl, quinolinyl, furanyl, thienyl, pyridinyl,
 anthracyl, benzothienyl, benzofuranyl or thieno[3,2-b]-
 pyridinyl, mono-, di- or trisubstituted with R⁸;
 5 HET is is a diradical of benzene, thiazole, thiophene, or furan,
 substituted with one or two R⁹ groups;
 Z is CO or a bond.
 m is 0-6; and
 n is 0,1, or 2.

10 2. The compounds of Claim 1, wherein,
 R¹ is H, lower alkyl, or lower fluorinated alkyl;
 R²⁻⁴ is independently H, lower alkyl, OR¹, halogen, or lower
 fluorinated alkyl;
 R⁷ is H, or lower alkyl; and
 15 Q₁ is morpholine, piperazine, piperidine, or pyrrolidine.

3. The compounds of Claim 1, wherein
 R¹ is lower alkyl;
 R²⁻⁴ is independently is H, or OR¹;
 20 R⁷ is H;
 Q₁ is morpholine;
 m is 2; and
 Z is a bond.

25 4. The compounds of Claim 1 which are:
 2-[1-(2-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-1-
 [morpholin-4-yl]ethanone;
 30 2-Methyl-3-(morpholin-4-yl)methyl-1-(1-naphthoyl)-1H-indole;
 2-Methyl-1-(1-naphthoyl)-1H-indol-3-ylacetic acid, methyl ester;
 1-(2-Chlorobenzoyl)-5-methoxy-2-methyl-3-(morpholin-4-ylmethyl)-
 1H-indole;

- 50 -

1-(2,3-Dichlorobenzoyl)-2-methyl-3-(morpholin-4-ylmethyl)-1*H*-indole;

1-(2,3-Dichlorobenzoyl)-5-methoxy-2-methyl-3-(morpholin-4-ylmethyl)- 1*H*-indole;

1-(1-Naphthoyl)-5-methoxy-2-methyl-3-(morpholin-4-ylmethyl)-1*H*-indole;

1-(2,3-Dichlorobenzoyl)-5-methoxy-2-methyl-3-(2-(morpholin-4-yl)ethyl)-1*H*-indole;

1-(2-Chlorobenzoyl)-2-methyl-3-(morpholin-4-ylmethyl)-1*H*-indole;

1-(1-Naphthoyl)-5-Methoxy-2-methyl-3-(2-(morpholin-4-yl)ethyl)-1*H*-indole;

1-(2-Chlorobenzoyl)-5-methoxy-2-methyl-3-(2-(morpholin-4-yl)ethyl)-1*H*-indole; or

1-(2-Chlorobenzoyl)-2-methyl-3-(2-(morpholin-4-yl)ethyl)-1*H*-indole.

5. A method of treating ocular hypertension and glaucoma, which comprises the step of ocularly administering a pharmacologically effective amount of a cannabimimetic pharmacological agent known to be selective for CB2 receptors to a patient in need of such treatment.

6. A method of treating ocular hypertension and glaucoma, which comprises the step of ocularly administering a pharmacologically effective amount of a compound of Claim 1, to a patient in need of such treatment.

7. A method of alleviating, treating or preventing, pulmonary disorders such as asthma, or chronic bronchitis; allergies and allergic reactions such as allergic rhinitis, contact dermatitis, or allergic conjunctivitis; inflammation such as arthritis or inflammatory

- 51 -

bowel disease; pain; disorders of the immune system such as lupus, or AIDS; allograft rejection; central nervous system diseases such as Tourette's syndrome, or Parkinson's disease, or Huntingdon's disease, or epilepsy, or depression, or manic depression; vomiting; or nausea and vertigo; in mammals, including humans, in need thereof, which comprises administering to such a mammal a pharmacologically effective amount of a compound of Claim 1.

8. A composition useful for treating ocular hypertension and glaucoma in a mammal, including humans, in need thereof, which comprises a pharmacologically effective amount of a cannabimimetic pharmacological agent, known to be selective for CB2 receptors, in a carrier or diluent buffered to a pH suitable for ocular administration.

9. A composition useful for treating ocular hypertension and glaucoma in a mammal, including humans, in need thereof, which comprises a pharmacologically effective amount of a cannabimimetic pharmacological agent of Claim 1, known to be selective for CB2 receptors, in a carrier or diluent buffered to a pH suitable for ocular administration.

10. An ocular hypertension and glaucoma pharmaceutical composition comprising a pharmacologically effective amount of a compound of formula (I), as defined in Claim 1, 2, 3 or 4, or a pharmaceutically acceptable salt thereof, or a diastereomer or enantiomer or mixtures thereof, in association with a pharmaceutically acceptable carrier.

11. A compound of formula (I), as defined in Claim 1, 2, 3 or 4, or a pharmaceutically acceptable salt thereof, or a diastereomer or enantiomer or mixtures thereof, for use in treating ocular hypertension and glaucoma; pulmonary disorders; allergies and allergic reactions; or inflammation; pain; disorders of the immune system; allograft rejection; central nervous system diseases; vomiting; or nausea and vertigo.

12. Use of a compound of formula (I), as defined in Claim 1, 2, 3 or 4, or a pharmaceutically acceptable salt thereof, or a diastereomer or enantiomer or mixtures thereof as a cannabimimetic pharmacological agent selected for CB2 receptors.

- 52 -

13. Use of a compound of formula (I), as defined in Claim 1, 2, 3 or 4, or a pharmaceutically acceptable salt thereof, or a diastereomer or enantiomer or mixtures thereof in the manufacture of a cannabimimetic pharmacological agent selective for CB2 receptors.

INTERNATIONAL SEARCH REPORT

Intern. Appl. Application No
PCT/CA 96/00080

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C07D209/14 A61K31/40 A61K31/405 C07D209/26		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 105 996 (MERCK & CO INC) 25 April 1984 see claim 1: Metindol = 1-(4-chlorobenzoyl)-5-methoxy- 2-methyl-1H-Indole-3-acetic acid ---	1-4
X	US,A,3 501 465 (SHEN TSUNG-YING ET AL) 17 March 1970 see claims; examples ---	1
X	US,A,3 489 770 (HERBST DAVID R) 13 January 1970 cited in the application see claims; examples ---	1-3
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search 10 April 1996		Date of mailing of the international search report 17.04.96
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016		Authorized officer De Jong, B

INTERNATIONAL SEARCH REPORT

Intern. al Application No
PCT/CA 96/00080

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 444 451 (STERLING DRUG INC) 4 September 1991 cited in the application see claims ---	1-4
X	JOURNAL OF MEDICINAL CHEMISTRY, vol. 16, no. 2, 1973 WASHINGTON US, pages 176-177, E.W. GLAMKOWSKI 'The aldehyde analog of indomethacin' see the whole document ---	1
X	US,A,3 336 194 (TSUNG-YIN SHEN ET AL.) 15 August 1967 see claims; examples ---	1-3
P,X	GB,A,2 283 745 (MERCK FROSST CANADA INC) 17 May 1995 see claims; examples ---	1-4
X	DATABASE CROSSFIRE Beilstein BRN=156339 & CHEM. BER., vol. 46, 1913 page 657 WEISSGERBER ---	1
X	DATABASE CROSSFIRE Beilstein BRN=448371 & ES,A,341 692 (GALLARDO S.A.) 1967 ---	1,2
X	DATABASE CROSSFIRE Beilstein BRN=447300 & NL,A,6 404 781 (MERCK) 1964 ---	1
X	DATABASE CROSSFIRE Beilstein BRN=451740 & US,A,3 161 654 (MERCK) 1963 ---	1
X	DATABASE CROSSFIRE Beilstein BRN=493436 & BE,A,615 395 (MERCK) 1962 ---	1
X	DATABASE CROSSFIRE Beilstein BRN=477362 & JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS, 1973 LETCHWORTH GB, pages 13-14, -----	1

2
5

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA96/00080

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 5-7 are directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
The search for claims 1 and 2 resulted in a large number of novelty destroying compounds. The search for these claims was not complete for economical reasons. (Claims 1 and 2 have been searched incompletely)
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Intern. al Application No
PCT/CA 96/00080

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0105996	25-04-84	NONE	
US-A-3501465	17-03-70	CH-A- 485718 DE-A- 1595940 FR-M- 5205 FR-A- 1472042 GB-A- 1109884 NL-A- 6508553	15-02-70 12-02-70 03-07-67 24-05-67 03-01-66
US-A-3489770	13-01-70	US-A- 3481953 US-A- 3487091 US-A- 3489429 US-A- 3494920	02-12-69 30-12-69 13-01-70 10-02-70
EP-A-0444451	04-09-91	US-A- 5068234 AU-B- 638795 AU-B- 7122291 CA-A- 2035711 IL-A- 97313 JP-A- 7041475 NO-B- 177006 US-A- 5324737	26-11-91 08-07-93 29-08-91 27-08-91 31-07-95 10-02-95 27-03-95 28-06-94
US-A-3336194	15-08-67	BE-A- 647413 CH-A- 460779 CH-A- 462169 FR-A- 1567853 GB-A- 1058984 NL-A- 6404781 US-A- 3285908	30-10-64 23-05-69 02-11-64 15-11-66
GB-A-2283745	17-05-95	US-A- 5436265	25-07-95

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ ~~FADED~~ TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ ~~LINE~~ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.